Since joining 5AM Ventures in 2003 as a venture partner, Scott Rocklage has played a critical role in the production and approval of three lines of drug by the U.S. Food and Drug Administration (FDA).
His visionary leadership, excellent management skills and solid academic background steeped in Chemistry saw the company develop Omniscan, Teslascan and Cubicin. Additionally, he has spearheaded the company’s efforts towards developing new drugs, some of which are currently under clinical trials.
Currently serving as a managing partner at 5AM Ventures, Scott has developed his strategic leadership skills through years of experience not only as a company executive but also as a research scientists and a scholar. His over three decades of professional experience has helped him guide 5AM Ventures towards greater operational success.
Career Background and Board Membership
Scott Rocklage has served in a wide range of roles in several pharmaceutical companies. Between 1994 and 2001, he served as the president of Pharmaceuticals Inc. while also serving as its chief executive officer up to 2003.
In 1990, he was appointed as the president and chief executive officer at Nycomed Salutar Inc. where he worked up to 1994. He also doubled up as the chairman, president and chief executive officer at Nycomed International Inc. between 1992 and 1994.
His long professional career has also seen him serve as the executive chairman at EntreMed, Ilypsa and Relypsa. Scott Rocklage also served within the research and development docket at Catalytica.
He currently holds several positions at the board of several companies. Scott is a board member at Relypsa where he serves as the chairman. He also serves at the board of WaveRx, VBI Vaccines, Pulmatrix, Novira Therapeutics, Rennovia and Epirus Biopharmaceuticals where he is a board member. He was also appointed to the board of associates at Whitehead Institute for Biomedical Research.
Scott Rocklage is a serial investor with investments in several pharmaceuticals, some of which he serves on their boards. In 2015, the Massachusetts Institute of Technology alumnus invested $25 million in Novira Therapeutics. He has also invested millions of dollars in Achaogen, Rennovia and Pulmatrix. He has made these investments through 5AM Ventures.
Learn more about Scott Rocklage: